Browsed by
Tag: HANE

HANE (HAE) 

HANE (HAE) 

A recent New England Journal of Medicine had three articles and an editorial about hereditary angioedema previously called hereditary angioneurotic edema.   

By way of reminder, HAE causes recurrent episodes of swelling that can affect various parts of the body:  face, tongue, throat, abdomen, extremities.  It is caused by a gene mutation in SERPING 1 which controls the production of C1-inhibitor.  In type 1 HAE there is a deficiency of the inhibitor, in type 2 the inhibitor protein is present but non-functional.  Lack of C1-inhibitor leads to excess levels of bradykinin which causes the tissue swelling.   

Current treatment of HAE is two pronged:  prevention and rescue.   This strategy is very similar to the approach to chronic asthma; that is, using a daily controller medicine but also having a rescue inhaler.  There are several preventative therapies available.  There are two types (one IV and one injected sub-Q) of purified C-1 inhibitor.  There are drugs that inhibit the procession of brady kinin kallikrein.  (An injectable monoclonal antibody and also an oral kallikrein inhibitor).     There are injectable kallikrein inhibitors and injectable brady kinin receptor blockers.  These medications can be used for both prevention and for rescue from acute attacks.   

One of the new medicines discussed in the journal is donidalorsen (an antisense oligonucleotide) that inhibits the messenger RNA that would otherwise stimulate excess kallikrein production.  Donidalorsen is an injected medication but unlike other kallikrein drugs that require more frequent injection, it can be given every two months.   

The other new drug that was discussed in the journal is sebetralstat an oral kallikrein inhibitor designed to treat acute attacks.  Currently the only rescue medicines for acute attacks are all either IV or injected.  Being IV or injected leads to barriers to compliance:  effort needed to transport, store and prepare the medication and reluctance to self-injection or infusion.  Also, if the swelling involves the hands the patient is incapable of self-administration.  These issues are especially problematic in teenagers and have led to withholding of treatment and subsequent hospitalization or death.  This makes an oral rescue medication a welcome option.   

For the sake of completeness there is a third type of HAE with normal C-1 inhibitor but excess brady kinin that can occur due to other protein abnormalities.  This group is very rare.   

New Treatment for HAE (HANE)

New Treatment for HAE (HANE)

The New England Journal of Medicine recently published research done at the University of California on a new treatment for hereditary angioneurotic edema (HANE) also called hereditary angioedema (HAE). 

HANE or HAE is a rare genetic disorder that leads to unpredictable, disabling and occasionally fatal episodes of swelling.  The swelling can occur in any part(s) of the body.  It is caused by uncontrolled activity of the contact system components factor X11a and plasma Kallikrein which leads to excessive release of a bradykinin which in turn causes leaky blood vessels (vascular permeability) with the resultant swelling from the fluid that leaks out of the blood vessels. 

The most common form is due to reduced production or reduced functionality of a controller protein called C-1-esterase inhibitor.  But there are other forms including ones with normal C-1-inhibitor.

This latter group has been difficult to treat with most current therapies because they work by increasing production of function of C-1-inhibitor replace it directly or inhibit Kallikrein or block the bradykinin receptor.  The currently available therapies can be used either to treat/stop acute attacks or prophylactically.  In general, they work quite well but not 100%.  That is why improved therapies are being researched. 

The new drug being researched is donidalorsen which is an antisense oligonucleotide that selectively inhibits plasma prekallikrein production.  (Say what?)   Donidalorsen inhibits the production of plasma prekallikrein by means of ribonuclease (RNase) enzyme that degrades messenger RNA that would otherwise lead to prekallikrein production.  The idea is by moving a step earlier in the domino-like chain of events by reducing prekallikrein this will prevent kallikrein and eventually bradykinin. 

The UC researchers have conducted a small trial in 32 patients with a 90% reduction in attacks.  Moreover, the medication was not prone to causing side effects.  Larger trials are underway.